Aktiesnakken — Juni 2010
-
Farlige frank
-
opsigelse "uden gyldig grund" vil forpligte genmab til at betale 12-24mdr løn
-
er skuffet
-
Pipeline: er der plads til yderligere investeringer i arzerra
-
er der råd til nye studier
-
vi har en robust pipeline
-
metode - følg linket til højre på forsiden af genmab.com
-
vi vil maximize vores muligheder
-
hvorfor var det lige, at de skulle vente i 30 timer med denne gang intetsigende munddiarre!?
-
ingen signifikante bekymringer for os
-
jo de har
-
Hvordan er mekanismerne i GSK aftalerne
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind